Business / Finance

RSS

Cambridge Heart fourth quarter total revenue decreases to $557,000

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its fourth quarter and full year ended December 31, 2011. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which will be filed with the Securities and Exchange Commission on March 30, 2012.

31 Mar 2012

Cortex reports net income of $832,000 for fourth quarter 2011

Cortex Pharmaceuticals, Inc. reported net income of approximately $832,000, or $0.01 per share, for the quarter ended December 31, 2011, compared with a net loss of approximately $984,000, or $0.01 per share, for the corresponding prior year quarter.

31 Mar 2012

Nile Therapeutics to sell 3.6 million shares of common stock

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has entered into a definitive agreement to sell 3.6 million shares of its common stock at a price per share of $0.40 for aggregate gross proceeds of $1.44 million.

31 Mar 2012

China Shenghuo 2011 total revenue increases 35% to $44.2 million

China Shenghuo Pharmaceutical Holdings, Inc., today reported financial results for the year ended December 31, 2011.

31 Mar 2012

PLC receives Brazilian government approval to market RenalGuard System

PLC Systems Inc., a company focused on innovative medical device technologies, today announced that it had received approval from the Brazilian government to market its innovative RenalGuard System in that country.

31 Mar 2012

Birner Dental Management Services 2011 revenue decreases 1.4% to $63.1M

Birner Dental Management Services, Inc., operators of PERFECT TEETH dental practices and Vantage Dental Implant Center, announced results for the year and quarter ended December 31, 2011.

31 Mar 2012

SPIN fourth quarter net revenue increases 53% to $5,212,165

Spine Pain Management, Inc., through its Chief Executive Officer, William F. Donovan, M.D., is pleased to report financial results for the year ended December 31, 2011.

31 Mar 2012

Bionovo 2011 total revenues decrease to $0.3 million

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced financial results for the year ended December 31, 2011.

31 Mar 2012

HIT raises $2.75 M USD in Series A funding

HIT Application Solutions, a leading healthcare technology development company, announced today the company has raised $2.75 M USD in its Series A funding effort.

31 Mar 2012

CIC total revenue for fiscal 2011 increases 82% to $1,546,000

Communication Intelligence Corporation, a leading supplier of electronic signature solutions and the recognized leader in biometric signature verification, today reported total revenue of $1,546,000 for the year ended December 31, 2011, an increase of $695,000 or 82%, compared to total revenue of $851,000 in the prior year.

31 Mar 2012

ChemoCentryx fourth quarter revenues increase to $26.1 million

ChemoCentryx, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2011.

31 Mar 2012

Oncothyreon proposes underwritten public offering of common stock

Oncothyreon Inc. today announced its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering.

29 Mar 2012

OncoSec Medical closes sale of 31,000,000 shares of common stock in registered public offering

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today the closing of the sale to institutional investors of an aggregate of 31,000,000 shares of its common stock at $0.25 per share in a registered public offering.

29 Mar 2012

Roche announces increase in offer price for outstanding Illumina shares

Roche announced today that it has increased its offer price for all outstanding publicly-held shares of Illumina, Inc. to US$ 51.00 per share in cash.

From Illumina, Inc. 29 Mar 2012

Southfield Capital acquires majority ownership of BioPharm

Southfield Capital, a private investment firm focused on the lower middle-market, announced today that it has acquired majority ownership of BioPharm Communications.

29 Mar 2012

Sientra closes $65M Series C financing

Sientra, a privately-held medical device company focused on the aesthetic and plastic surgery markets, announced today that it closed on its $65 million Series C financing led by Abingworth and with participation by Clarus Ventures, OrbiMed Advisors and all other insiders.

29 Mar 2012

Galectin closes underwritten public offering of 1,333,361 units

Galectin Therapeutics Inc. today announced it has closed its underwritten public offering of 1,333,361 units (including 173,916 units that were offered and sold by Galectin pursuant to the exercise in-full of the underwriter's over-allotment option) at a price to the public of $9.00 per unit, with each unit consisting of two common voting shares, par value $0.001 per share and one warrant to purchase one share of Common Stock.

29 Mar 2012

EpiCept to receive $0.97M in public offering

EpiCept Corporation announced today that it has entered into a definitive agreement with a single life science focused institutional investor for the purchase of 1,065 shares of its new Series B 0% Convertible Preferred Stock at $1,000 per share, which are convertible into an aggregate of approximately 6.3 million shares of its common stock, and five-year warrants to purchase up to approximately 3.1 million shares of its common stock at an exercise price of $0.17 per share that are immediately exercisable.

29 Mar 2012

CHVI announces new member - Healthper

The nonprofit Center for Health Value Innovation (CHVI) announced today that Healthper, Inc., a social game-based health engagement and achievement platform, has joined as a member.

29 Mar 2012

Strand Diagnostics to receive $30 million in funding from NantWorks

Strand Diagnostics, LLC, maker of the know error system, and NantWorks, LLC announced that they have entered into an agreement whereby Strand will receive up to $30 million in funding from NantWorks, LLC over the next 3 years.

29 Mar 2012